All government hospitals in Bhopal to have dialysis unit by January 26 - Times of India |
BHOPAL: State cabinet headed by chief minister Shivraj Singh Chouhan on Tuesday decided to install dialysis machines in every government hospital by January 26. It was also decided that the family of a student will not have to repay the education loan in case of grad's death in an accident or for any other reason.
Speaking to media persons, minister for health and government spokesman Narottam Mishra said, "State government and concerning bank will repay the student loan and the family will not be required to repay the same. This way, at least there will be no financial burden on families after having gone through the trauma of a child's death." The scheme will also be applicable in cases of permanent disability.
Mishra said that loan-borrower students will be connected with two new insurance schemes launched by Narendra Modi Union government for social security. Annual premium of Pradhan Mantri Suraksha Bima Yojana and Pradhan Mantri Jeevan Jyoti Yojana is Rs 12 and Rs 330 respectively. Duration of education loan is generally between 7 and 10 years. On an average for 10 years, burden of only Rs 3,420 will fall on a student, a government release stated. Insurance cover of Rs 4 lakh will be provided under both policies.
"A formula is being worked out by which in case of a student's demise, 50% of the loan amount will be paid by the state and the other 50% could come from the insurance schemes, so banks can waive off repayment," said Narottam Mishra.
Besides, cabinet approved amendment of centralized system for contractors' registration. Under it, rates will become competitive and experienced contractors will be available. Registration of an unregistered contractor can now be done without test of experience if he meets pre-qualification terms. Condition of character certificate has been abolished.
|
Doctors will be able to look at your beating heart or at your colon in 3-D virtual reality. |
Using virtual reality, on the other hand, a doctor can “fly through” each segment of the colon in 3D space. The difference is extraordinary. One of the nation’s top specialists at UCSF (who we’re working with currently) is completing the procedure in just 5-10 minutes using interactive VR. And she’s finding her ability to correctly identify cancerous lesions is up a full 100%.
|
Scots pensioner 'drove 66932 miles for dialysis' - Scotsman |
A SCOTTISH pensioner has travelled the equivalent of more than twice round the world in two years to access dialysis treatment from the NHS.
Mary McKay, 75, has clocked up a staggering 66,932 road miles to access the treatment she needs three times a week.
The grandmother had no choice but to make the long journey from her home in Campbeltown to the Vale of Leven Hospital in Alexandria, because there was no dialysis unit in Argyll. Having travelled 690 miles a week to and from the Vale of Leven for 17 and a half months – and even further to Glasgow’s Western and Royal infirmaries for earlier dialysis sessions – Mrs McKay says it’s an experience no-one else should ever have to endure.
Going to the Edinburgh Festival? Find out which shows to see on our dedicated site >>
She said: “I have never been abroad. But when the miles are added up, for my dialysis treatment, I have been round the world twice – and didn’t know it.”
Mrs McKay, who had to leave her house at 8:30am for the hospital journey and didn’t get back home until 8pm, said: “For nearly two years I have been on dialysis and all the travelling going down the road and back three times a week was exhausting, I know how I felt, it was horrendous. I was tired all the time.”
Now, after a community led campaign raised more than £100,000 in a year, a new dialysis unit has opened for business at Campbeltown Hospital.
Mrs McKay said: “It’s only two or three minutes for me to get there by Red Cross car now. It’s great.”
Her husband, Neil, said: “She is over the moon now, it was terrible what she had to do before, I got in touch with politicians from all the parties to try and get something done.”
While space was available for a unit in Campbeltown Hospital, the cash-strapped health board, which has trained specialist staff for the new unit, was short of cash to buy the necessary equipment. Donald Kelly, chairman of Kintyre Dialysis Campaign Group, said the community response had been amazing.
He said: “This is the fastest ever dialysis campaign, raising £100,000 in a year. But I feel quite strongly that the NHS should be providing this kind of unit. If there is a requirement for a service in a particular area I think the NHS should be providing it, it shouldn’t be up to the community to self fund.”
Stephen Whiston, head of planning, contracting and performance at NHS Highland, said: ““This is a pilot project and we will need to evaluate clinical outcomes for our patients, demand and utilisation across the area and ongoing financial resources. Should this model of service prove to be successful we can see it being appropriate for other parts of rural Scotland.”
|
Nxstage Medical, Inc. (NXTM) Files Form 4 Insider Selling : Robert S. Brown ... - Insider Trading Report |
Nxstage Medical, Inc. (NXTM): Robert S. Brown , President, NxStage Kidney Care of Nxstage Medical, Inc. sold 10,825 shares on Aug 17, 2015. The Insider selling transaction was disclosed on Aug 18, 2015 to the Securities and Exchange Commission. The shares were sold at $18.30 per share for a total value of $198,097.50.
Currently the company Insiders own 2.3% of Nxstage Medical, Inc. Company shares. In the past six months, there is a change of -6.42% in the total insider ownership. Institutional Investors own 94.4% of Company shares. During last 3 month period, -1.93% of total institutional ownership has changed in the company shares. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the (President) of Nxstage Medical, Inc., Turk Joseph E Jr had sold 3,252 shares worth of $57,690 in a transaction dated August 12, 2015. In this transaction, 3,252 shares were sold at $17.74 per share. Shares of NxStage Medical, Inc. (NASDAQ:NXTM) rose by 1.56% in the past week and 28.57% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 0.88% and the outperformance increases to 30.73% for the last 4 weeks. Nxstage Medical, Inc. is up 9.27% in the last 3-month period. Year-to-Date the stock performance stands at 1.9%.
The company shares have rallied 37.93% in the past 52 Weeks. On April 27, 2015 The shares registered one year high of $19.63 and one year low was seen on September 16, 2014 at $11.5. The 50-day moving average is $14.92 and the 200 day moving average is recorded at $16.69. S&P 500 has rallied 6.56% during the last 52-weeks. NxStage Medical, Inc. (NASDAQ:NXTM) : On Friday heightened volatility was witnessed in NxStage Medical, Inc. (NASDAQ:NXTM) which led to swings in the share price. The shares opened for trading at $18.14 and hit $18.4099 on the upside , eventually ending the session at $18.27, with a gain of 0.27% or 0.05 points. The heightened volatility saw the trading volume jump to 335,709 shares. The 52-week high of the share price is $19.63 and the company has a market cap of $1,159 million. The 52-week low of the share price is at $11.5 . NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Companys primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.
|
|
|